Cost-effectiveness of Advair®: fluticasone propionate and salmeterol combination

Authors: Tano, Benoit; Pathak, Dev; Hoffmann, Stephen

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 3, Number 6, December 2003 , pp. 741-747(7)

Publisher: Expert Reviews

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The National Heart, Lung and Blood Institute guidelines for the treatment of asthma suggest that inhaled corticosteroids, with the addition of a long-acting bronchodilator, may be the most effective long-term control medication for asthma. Five inhaled corticosteroids are approved for use in the USA, including beclomethasone dipropionate, budesonide, flunisolide, triamcinolone acetonide and fluticasone propionate. Fluticasone propionate (Flixotide®) and the long-acting β2 agonist salmeterol (Serevent®), are now available in the USA together in an easy to use dry powder inhaler Advair®. The cost-effectiveness of this combination in the treatment of persistent asthma is reviewed. This review evaluates all the cost-effectiveness studies comparing fluticasone propionate and salmeterol from two separate inhalers or one single inhaler available in the literature. Cost-effectiveness was compared with inhaled corticosteroids alone, leukotriene receptor antagonists and other combination therapies in patients with persistent asthma.

Keywords: advair; asthma; cost-effectiveness; healthcare

Document Type: Research article

DOI: 10.1586/14737167.3.6.741

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A